FdaApplication
ANDA 204920
Identifiers
- fda_app_no: ANDA204920
Properties
| Property | Value |
|---|---|
| applicant_name | PHARMOBEDIENT CONSULTING LLC |
| application_type | ANDA |
| approval_date | 2021-07-20 |
Products (2)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| NAPROXEN AND ESOMEPRAZOLE MAGNESIUM | ESOMEPRAZOLE MAGNESIUM; NAPROXEN | EQ 20MG BASE;500MG | TABLET, DELAYED RELEASE;ORAL |
| NAPROXEN AND ESOMEPRAZOLE MAGNESIUM | ESOMEPRAZOLE MAGNESIUM; NAPROXEN | EQ 20MG BASE;375MG | TABLET, DELAYED RELEASE;ORAL |
2 products